First Published Clinical Trial Using Live Biotherapeutic Candidate in COVID-19 Patients Suggests Role In Improving Outcome standard
ROCKVILLE, Md., July 13, 2020 ExeGi Pharma LLC, a U.S.-based company focused on developing and commercializing products targeting the human microbiome, including live biotherapeutic products (LBPs), announced today the results of a 70-patient clinical trial evaluating a new biologic drug candidate in hospitalized COVID-19 patients. The study was conducted in a hospital setting in Rome and published in the peer-reviewed journal Frontiers in Medicine. It compared outcomes of patients who received standard drug treatments alone or standard treatments combined with an oral bacteriotherapy. COVID-19 crisis exploded in Italy and clinicians struggled to navigate patient care. Investigators at Policlinico Umberto I, “Sapienza” University of Rome hypothesis that a bacterial formulation, with a specific biochemical and immunological profile, could trigger the production of ...
Continue Reading